Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Passaro

Showing results (901-910 of 950) with videos related to

Pageof 95
Sort By:
JAMA Internal Medicine|October 20, 2020
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical TrialCarlo Salvarani, Giovanni Dolci, Marco Massari, et al.
Children (Basel, Switzerland)|March 28, 2025
Diagnosis and Screening Strategies for Detection of Familial Hypercholesterolaemia in Children and Adolescents in Italy: A Survey from the LIPIGEN Paediatric GroupCristina Pederiva, Federica Galimberti, Manuela Casula, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2026
Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational ImpactMichele Carbone, Christopher Amos, Richard L Attanoos, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of the National Cancer Institute|April 5, 2017
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLCImane Chaib, Niki Karachaliou, Sara Pilotto, et al.
Nature Immunology|May 21, 2021
Clonally expanded EOMES<sup>+</sup> Tr1-like cells in primary and metastatic tumors are associated with disease progressionRaoul J P Bonnal, Grazisa Rossetti, Enrico Lugli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2023
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyA Passaro, J Wang, Y Wang, et al.
Cancer|May 30, 2026
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS RegistryFrancesco Passiglia, Antonio Passaro, Eleonora Gariazzo, et al.
The Lancet. Oncology|June 17, 2020
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort studyMarina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 StudyNatasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.
Pageof 95

Showing results (901-910 of 950) with videos related to

Sort By:
Pageof 95
JAMA Internal Medicine|October 20, 2020
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical TrialCarlo Salvarani, Giovanni Dolci, Marco Massari, et al.
Children (Basel, Switzerland)|March 28, 2025
Diagnosis and Screening Strategies for Detection of Familial Hypercholesterolaemia in Children and Adolescents in Italy: A Survey from the LIPIGEN Paediatric GroupCristina Pederiva, Federica Galimberti, Manuela Casula, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2026
Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational ImpactMichele Carbone, Christopher Amos, Richard L Attanoos, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of the National Cancer Institute|April 5, 2017
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLCImane Chaib, Niki Karachaliou, Sara Pilotto, et al.
Nature Immunology|May 21, 2021
Clonally expanded EOMES<sup>+</sup> Tr1-like cells in primary and metastatic tumors are associated with disease progressionRaoul J P Bonnal, Grazisa Rossetti, Enrico Lugli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2023
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyA Passaro, J Wang, Y Wang, et al.
Cancer|May 30, 2026
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS RegistryFrancesco Passiglia, Antonio Passaro, Eleonora Gariazzo, et al.
The Lancet. Oncology|June 17, 2020
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort studyMarina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 StudyNatasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.
Pageof 95